Carl P. Sherr & Co. LLC Sells 556 Shares of Eli Lilly and Company (NYSE:LLY)

Carl P. Sherr & Co. LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 9.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,317 shares of the company’s stock after selling 556 shares during the period. Eli Lilly and Company comprises approximately 1.9% of Carl P. Sherr & Co. LLC’s holdings, making the stock its 10th largest position. Carl P. Sherr & Co. LLC’s holdings in Eli Lilly and Company were worth $3,099,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. JGP Wealth Management LLC grew its position in Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after buying an additional 16 shares in the last quarter. Cassia Capital Partners LLC boosted its holdings in shares of Eli Lilly and Company by 1.8% in the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after acquiring an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after acquiring an additional 17 shares during the period. Patton Albertson Miller Group LLC lifted its position in Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares during the period. Finally, Valley Wealth Managers Inc. boosted its stake in Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LLY. Barclays upped their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Citigroup raised their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Bank of America lifted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Morgan Stanley upped their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.5 %

Eli Lilly and Company stock traded down $4.03 during trading hours on Wednesday, hitting $746.74. The company had a trading volume of 2,569,799 shares, compared to its average volume of 2,215,511. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a market capitalization of $709.52 billion, a P/E ratio of 128.75, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The firm’s fifty day moving average is $763.51 and its 200-day moving average is $657.01.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.09 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.